Literature DB >> 14996625

Current strategies for managing interstitial cystitis.

C Lowell Parsons1.   

Abstract

Interstitial cystitis is a relatively common disorder that can be treated successfully in the majority of cases. Symptoms can be effectively controlled, and disease pathophysiology addressed, using a multimodal medical regimen based on heparinoid therapy. As appropriate to the individual patient, heparinoid therapy is supplemented by oral medications aimed at reversing neural upregulation and controlling any allergies. A new and promising adjunct to the multimodal regimen is an intravesical therapeutic solution that combines pentosan polysulfate or heparin with lidocaine and sodium bicarbonate. Preliminary results indicate this therapeutic solution provides immediate temporary relief of symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996625     DOI: 10.1517/14656566.5.2.287

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

2.  Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis.

Authors:  Christopher D Engles; Paul J Hauser; Shivon N Abdullah; Daniel J Culkin; Robert E Hurst
Journal:  Urology       Date:  2011-12-02       Impact factor: 2.649

Review 3.  Resiniferatoxin in the treatment of interstitial cystitis: a systematic review.

Authors:  Eleni G Mourtzoukou; Christos Iavazzo; Matthew E Falagas
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.